Egypt: A recent systematic review and meta-analysis evaluating the efficacy and safety of spironolactone in patients with acne vulgaris suggests that the drug significantly improves acne ...

Congested skin is a common issue that occurs when dead skin cells, oil, sweat, and dirt block the pores, leading to a dull appearance or acne. Here’s what you can do to treat it.

Mayo Clinic researchers have identified a targeted therapy that could bring relief to people living with lichen planus, a ...

Phyla, a new skincare brand backed by Ryan Reynolds and Shiseido, uses natural phage technology to clear up pimples.

A TEEN boy’s face suddenly began burning and his spot-covered skin peeled away after a filler injection went disastrously wrong. Charlie Michael Baker was just 17 when he was lured into ...

Body acne, in particular, can be especially painful and difficult to treat since it often pops up on larger, harder-to-reach areas. Beyond acne body washes, salicylic acid body sprays are one of the ...

Less common white bump causes worth noting are: Flat warts: “These small, skin-colored bumps are caused by specific strains ...

For more of the Cut’s favorite fashion, beauty, and home finds, sign up for the weekly Cut Shop Newsletter.,, Blake Newby was 13 years old when hormonal acne appeared on her fac ...

Acne, commonly known as pimples, is not linked to cancer. Pimples result from blocked pores, hormonal changes, or stress, and are non-cancerous. Howev ...

I turned 50 during the pandemic and, like most people, I put off all nonessential health care, including my shingles vaccine. Big mistake. When the telltale red bumps of shingles cropped up on my ...

This is Dermata's first issued U.S. patent for XYNGARI, which uses its Spongilla technology to topically treat acne -- Dermata expects to announce topline results from its STAR-1 Phase 3 XYNGARI clini ...

This is Dermata's first issued U.S. patent for XYNGARI™, which uses its Spongilla technology to topically treat acne - - Dermata expects to announce topline results from its STAR-1 Phase 3 XYNGARI™ ...